These findings demonstrated that pioglitazone’s mechanism of action is primarily through the induction of apoptosis and, to a lesser extent, inhibition of proliferation, offering promising potential for its use as a chemopreventive agent across multiple NSCLC subtypes with p53 statuses [68]. The gene discussed is TP53; the disease is non-small cell lung carcinoma.